| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager | 2025-09-03 | 0001736814 |
| Decheng Capital Management III (Cayman), LLC | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | Decheng Capital Management III (Cayman), LLC, By /s/Xiangmin Cui, Manager | 2025-09-03 | 0001747821 |
| Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | Decheng Capital China Life Sciences USD Fund II, L.P., By Decheng Capital Management II (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager | 2025-09-03 | 0001650291 |
| Decheng Capital Global Healthcare Fund (Master), LP | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | Decheng Capital Global Healthcare Fund (Master), LP, By Decheng Capital Global Healthcare GP, LLC, its General Partner, By Decheng Capital LLC, its Manager, By /s/ Xiangmin Cui, Manager | 2025-09-03 | 0001949026 |
| Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | Decheng Capital Global Healthcare GP, LLC, By Decheng Capital LLC, its Manager, By /s/ Xiangmin Cui, Manager | 2025-09-03 | 0001949027 |
| Cui Xiangmin | 10%+ Owner | C/O DECHENG CAPITAL, 3000 SAND HILL ROAD, BLDG. 2, SUITE 110, MENLO PARK | /s/ Xiangmin Cui | 2025-09-03 | 0001487815 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BYSI | Ordinary Shares | Sale | -$1.39K | -800 | -0.04% | $1.74 | 1.91M | Aug 29, 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. | F1, F2 |
| transaction | BYSI | Ordinary Shares | Sale | -$4.98K | -2.8K | -0.15% | $1.78 | 1.91M | Sep 2, 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. | F2, F3 |
| transaction | BYSI | Ordinary Shares | Sale | -$2.3K | -1.27K | -0.07% | $1.81 | 1.9M | Sep 3, 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. | F2, F4 |
| holding | BYSI | Ordinary Shares | 1.62M | Aug 29, 2025 | By Decheng Capital China Life Sciences USD Fund II, L.P. | F5 | |||||
| holding | BYSI | Ordinary Shares | 892K | Aug 29, 2025 | By Decheng Capital Global Healthcare Fund (Master), LP | F6 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| F6 | These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |